Almac invests £16m in oral dose development site

Almac Group has confirmed a  £16 million investment to expand its formulation and analytical development services

The company announced it will operate a proportion of the science, technology and enterprise park on Charnwood Campus in Loughborough, England.

Almac will occupy the formulation development and analytical testing facilities at the site which will combine with its development and GMP services offered from its Craigavon NI Headquarters. 

Almac is recommissioning the formulation development, clinical manufacturing and analytical testing facilities with operations focusing initially on expanding both non-potent and potent solid oral dose processing. 

With an initial investment into the Charnwood site of £16m Almac said its operational start date is targeted for Q1 2017.

Graeme McBurney, managing director, Almac Pharma Services said: “As we experience increased client demand for our pharmaceutical development and niche commercial manufacturing services, this latest expansion will significantly enhance Almac’s offering, increasing capacity and capability and further demonstrating our continued commitment to support our global clients in the development and manufacturing of their drug products.”